REFERENCES
- Drevs J, Schmidt-Gersbach CI, Mross K, Medinger M, Mueller M, Steward W, Laurent D, Lee L, Dugan M, Henry A, Marme D, Unger C. Surrogate markers for the assessment of biological activity of the VEGF-receptor inhibitor PTK787/ZK 222584 (PTK/ZK) in two clinical phase I trials. Proc Am Soc Clin Oncol 2002;21:337.
- Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D, Steward WP. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005;23:4162–4171.
- Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007;14:285–294.
- Bran B, Bran G, Hormann K, Riedel F. The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. Int J Oncol 2009;34:255–261.
- Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes H-P, Menger MD, Ullrich A, Vajkoczy P. Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2003;18:338–340.
- Hasumi Y, Klosowska-Wardega A, Furuhashi M, Ostman A, Heldin CH, Hellberg C. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling. Int J Cancer 2007;121:2606–2614.
- Sennino B, Kuhnert F, Tabruyn SP, Mancuso MR, Hu-Lowe DD, Kuo CJ, McDonald DM. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. Cancer Res 2009;69:4527–4536.
- Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z, Kaminker J, Ferrara N. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009;15:21–34.
- Hecht JR, Trarbach T, Jaeger E, Hainsworth J, Wolff R, Lloyd K, Bodoky G, Borner M, Laurent D, Jacques C. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/ leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). ASCO Meeting Abstracts 2005;23:LBA3.
- Koehne C, Bajetta E, Lin E, Van Cutsem E, Hecht J, Douillard J, Moore M, Germond C, Laurent D, Jacques C. Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). ASCO Meeting Abstracts 2006;24:3508
- Major P, Trarbach T, Lenz H, Kerr D, Pendergrass K, Douillard J, Chen B, Laurent D, Jacques C, Van Cutsem E. A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. ASCO Meeting Abstracts 2006;24:3529